Close Menu

HER2 Biomarkers

News and reporting on HER2 biomarkers.

Hal Barron, Genentech's chief medical officer, said that "by using [Dako's] diagnostics to help identify the right patients" who will benefit from treatment, Genentech hopes to make Herceptin "the first targeted option for advanced HER2-positive stomach cancer."

CAP and ASCO issued new guidelines to improve accuracy of immunohistochemistry-based ER and PgR testing in breast cancer. The groups estimate that between 10 percent and 20 percent of IHC test results throughout the world may be inaccurate, yielding false-positive or false-negative results.

In the retrospective meta-analysis presented at the European Breast Cancer Conference this week, around 67 percent of patients with CEP17 tumors treated with anthracyclines experienced recurrence-free survival and overall survival in this group was 63 percent.

Genomic Health has been conducting a number of studies to examine how well its RT-PCR-based Oncotype DX test compares to IHC and FISH for assessing the HER2 status of breast cancer patients.

Pages

The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.

The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.

News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.

In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.